Novavax shares skyrocket on European vax pact

Shares of Rockville, MA-based Novavax shot up more than 80 percent on Tuesday afternoon after the developer announced a licensing deal covering its use of virus-like particles in new vaccines.

Spain's Rovi Pharmaceuticals Laboratories plans to use Novavax's technology to develop exclusive new seasonal and pandemic vaccines for Spain and Portugal. Rovi also gets a non-exclusive license for Europe, Latin America and Africa. And Rovi is making a $3 million equity investment in Novavax in the partnership deal.

A non-profit foundation, jointly sponsored by ROVI and the Spanish authorities, will be formed and funded with a 25 million euro credit line from the Spanish government to support Phase III clinical development and other studies necessary to achieve marketing authorization of the VLP influenza vaccines in the European Union in 2012.

The deal represents a coup for Novavax, which has been looking to partner up as a way to gain new capital. "We continue to discuss opportunities with other pharmaceutical companies and governments to implement this compelling influenza vaccine technology around the globe," CEO Rahul Singhvi says.

- read the Novavax release
- read the report from the Washington Business Journal

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.